Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined
with standard first-line chemotherapy will have on you and non-small cell lung cancer
(NSCLC). The investigational drug Pirfenidone is being combined with standard chemotherapy in
participants with advanced non-small cell lung cancer. Pirfenidone is approved to treat
idiopathic pulmonary fibrosis (IPF) but it isn't currently approved to treat non-small cell
lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute